On March 9, 2022 Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, reported that an abstract has been accepted for poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, Targovax, MAR 9, 2022, View Source [SID1234609747]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstracts show ONCOS-102 drives pro-inflammatory modulation of the tumor micro-environment in PD-1 refractory melanoma tumors. ONCOS-102 is associated with efficient viral gene expression and strong, sustained activation of immune-related genes, which may be targets for future combinations of ONCOS-102 and immune-modulators beyond PD-1/PD-L1 inhibitors.
The abstract has been released on the AACR (Free AACR Whitepaper) website today (View Source). The poster is scheduled for presentation Monday 11 April 2022 and will be available on Targovax’s website after the presentation.
Poster title:
Modulation of immune gene expression by intra-tumoral oncolytic adenovirus ONCOS-102 is associated with clinical response in anti-PD-1 refractory/resistant melanoma
Date and time:
Monday 11 April 2022, 13:30- 17:00 CDT / 20:30-24:00 CET
Location:
New Orleans Convention Center, Exhibit Halls D-H, Poster Section 31
Session category:
Clinical research excluding trials
Session title:
Immune response to therapies / immune monitoring and clinical correlate
Poster number:
1983
Presenter:
Thomas Birkballe Hansen, VP Research, Targovax
About AACR (Free AACR Whitepaper)
The AACR (Free AACR Whitepaper) Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR (Free AACR Whitepaper) Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.